Simulations Plus Beheer
Beheer criteriumcontroles 3/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Shawn O'Connor
Algemeen directeur
US$1.9m
Totale compensatie
| Percentage CEO-salaris | 25.1% |
| Dienstverband CEO | 6.4yrs |
| Eigendom CEO | n/a |
| Management gemiddelde ambtstermijn | 3.9yrs |
| Gemiddelde ambtstermijn bestuur | 3.7yrs |
Recente managementupdates
Recent updates
Simulations Plus: Declining Margins Are A Problem
Aug 22Simulations Plus: Steady Growth, But What About The Margins?
Jul 10Simulations Plus: Reliance On Consulting And Acquisitions Creates Doubts
May 14Why We're Not Concerned About Simulations Plus, Inc.'s (NASDAQ:SLP) Share Price
Mar 29
Capital Allocation Trends At Simulations Plus (NASDAQ:SLP) Aren't Ideal
Feb 09Simulations Plus: Questionable Whether It Will Benefit Or Be Hurt By Generative AI
Feb 01We Like Simulations Plus' (NASDAQ:SLP) Earnings For More Than Just Statutory Profit
Jan 12Capital Allocation Trends At Simulations Plus (NASDAQ:SLP) Aren't Ideal
Nov 06Estimating The Intrinsic Value Of Simulations Plus, Inc. (NASDAQ:SLP)
Sep 06Here's What's Concerning About Simulations Plus' (NASDAQ:SLP) Returns On Capital
Jun 28Some Investors May Be Worried About Simulations Plus' (NASDAQ:SLP) Returns On Capital
Feb 10With EPS Growth And More, Simulations Plus (NASDAQ:SLP) Makes An Interesting Case
Nov 23A Look At The Intrinsic Value Of Simulations Plus, Inc. (NASDAQ:SLP)
Oct 21Here's What's Concerning About Simulations Plus' (NASDAQ:SLP) Returns On Capital
Sep 19Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Aug 31 2024 | n/a | n/a | US$10m |
| May 31 2024 | n/a | n/a | US$10m |
| Feb 29 2024 | n/a | n/a | US$11m |
| Nov 30 2023 | n/a | n/a | US$11m |
| Aug 31 2023 | US$2m | US$487k | US$10m |
| May 31 2023 | n/a | n/a | US$10m |
| Feb 28 2023 | n/a | n/a | US$10m |
| Nov 30 2022 | n/a | n/a | US$11m |
| Aug 31 2022 | US$1m | US$450k | US$12m |
| May 31 2022 | n/a | n/a | US$12m |
| Feb 28 2022 | n/a | n/a | US$12m |
| Nov 30 2021 | n/a | n/a | US$10m |
| Aug 31 2021 | US$1m | US$444k | US$10m |
| May 31 2021 | n/a | n/a | US$12m |
| Feb 28 2021 | n/a | n/a | US$11m |
| Nov 30 2020 | n/a | n/a | US$10m |
| Aug 31 2020 | US$739k | US$350k | US$9m |
| May 31 2020 | n/a | n/a | US$9m |
| Feb 29 2020 | n/a | n/a | US$9m |
| Nov 30 2019 | n/a | n/a | US$9m |
| Aug 31 2019 | US$425k | US$325k | US$9m |
| May 31 2019 | n/a | n/a | US$8m |
| Feb 28 2019 | n/a | n/a | US$7m |
| Nov 30 2018 | n/a | n/a | US$9m |
| Aug 31 2018 | US$618k | US$54k | US$9m |
Compensatie versus markt: De totale vergoeding ($USD 1.94M ) Shawn } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.40M ).
Compensatie versus inkomsten: De beloning van Shawn is het afgelopen jaar met meer dan 20% gestegen, terwijl de winst van het bedrijf met meer dan 20% is gedaald.
CEO
Shawn O'Connor (64 yo)
6.4yrs
Tenure
US$1,942,004
Compensatie
Mr. Shawn M. O'Connor has been Chief Executive Officer of Simulations Plus, Inc. since June 26, 2018. Mr. Shawn M. O'Connor joined Simulations Plus, Inc. in June 2018. Mr. O'Connor served as Chief Executiv...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder & Chairman | 28.3yrs | US$199.99k | 17.36% $ 94.8m | |
| Chief Executive Officer | 6.4yrs | US$1.94m | geen gegevens | |
| COO, CFO & Secretary | 3.9yrs | US$880.90k | 0.010% $ 57.2k | |
| President of PBPK & Cheminformatics Solutions | 1.4yrs | US$728.14k | 0.40% $ 2.2m | |
| President of Clinical Pharmacology & Pharmacometrics Services | 5.1yrs | US$722.10k | 0.34% $ 1.9m | |
| Accounting Manager | no data | geen gegevens | geen gegevens | |
| Chief Science Officer | 4.2yrs | geen gegevens | geen gegevens | |
| VP of Corporate Counsel & Personal Data Protection Officer | no data | geen gegevens | geen gegevens | |
| Marketing Manager | less than a year | geen gegevens | geen gegevens | |
| Executive Director of Human Resources | 2.8yrs | geen gegevens | geen gegevens | |
| Chief Science Officer - Quantitative Systems Pharmacology | no data | geen gegevens | geen gegevens | |
| President of Clinical Pharmacology & Pharmacometrics Solutions | no data | geen gegevens | geen gegevens |
3.9yrs
Gemiddelde duur
60yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van SLP wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.9 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder & Chairman | 28.3yrs | US$199.99k | 17.36% $ 94.8m | |
| lead Independent Director | 7.5yrs | US$199.99k | 0.035% $ 190.5k | |
| Independent Director | 5.5yrs | US$189.99k | 0.034% $ 185.4k | |
| Member of Scientific Advisory Board | 3.7yrs | geen gegevens | geen gegevens | |
| Chairman of Scientific Advisory Board | 3.7yrs | geen gegevens | geen gegevens | |
| Independent Director | 9.9yrs | US$199.99k | 0.021% $ 116.8k | |
| Member of Scientific Advisory Board | 3.7yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 3.7yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 3.7yrs | geen gegevens | geen gegevens | |
| Independent Director | 2.9yrs | US$187.49k | 0.034% $ 187.1k |
3.7yrs
Gemiddelde duur
70yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van SLP wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.7 jaar).